Celgene acquires first asset, marizomib, from partner Triphase Accelerator
By Natasha Berry
Pharma Deals Review: Vol 2016 Issue 12 (Table of Contents)
Published: 14 Dec-2016
DOI: 10.3833/pdr.v2016.i12.2210 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
From its long-standing partner, Triphase Accelerator Corporation, Celgene has acquired its first asset, marizomib, which is being developed for multiple myeloma and glioma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS